A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19
An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 WHO Grade 3&4 (NOCoV2)
Sponsor: Thirty Respiratory Limited
Listed as NCT04460183, this PHASE2/PHASE3 trial focuses on COVID-19 and remains completed. Sponsored by Thirty Respiratory Limited, it has been updated 10 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Feb 2022 — Jul 2022 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
-
Feb 2021 — Feb 2022 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Thirty Respiratory Limited
For direct contact, visit the study record on ClinicalTrials.gov .